MedTrace Logo

Impact of Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation

NCT04609930 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 143

Last updated 2021-12-23

No results posted yet for this study

Summary

The primary objective of this study is to determine the impact of anti-checkpoint immunotherapy on type 2 inflammation via a retrospective analysis of % eosinophilia.

Conditions

  • Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies

Interventions

DRUG

Anti-PD-1 or anti-PD-L1

Immunotherapy treatment via anti programmed death 1 and/or anti-programmed death ligand 1.

Sponsors & Collaborators

  • University Hospital, Montpellier

    lead OTHER

Principal Investigators

  • Jeremy Charriot, MD · University Hospital, Montpellier

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-30
Primary Completion
2021-08-31
Completion
2021-08-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04609930 on ClinicalTrials.gov